A Phase 3 interventional study of Inhaled Insulin and Subcutaneous insulin in Diabetes Mellitus, sponsored by Pfizer. Terminated at 92 sites in 4 countries. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2010-02-18.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies testing insulin in Diabetes Mellitus — 1 open to participants now, 2 under way, none of them phase 3. Insulin · Diabetes Mellitus.
Among the 51 studies testing insulin in Diabetes Mellitus, this one is the 6th largest by enrollment of the 49 interventional ones that give a count, is one of 2 that started in 2002, is one of 11 in phase 3, and was the 4th registered.
8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.
Browse Diabetes Mellitus studies →1 of the 51 studies testing insulin in Diabetes Mellitus is open now, in 1 country. Recruiting first, the newest first:
Ohio State University · Sites in United States
Ages 18+ · Women only
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.
This study: 35 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 12 · Phase 3 11 · Phase 4 12
First in 1994; this study’s year is marked. 2 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 635 is above the median of 80 across 6,025 interventional studies indexed under Diabetes Mellitus.
Median enrollment 74 across the 49 interventional studies. Of the 44 that completed or were terminated, 18 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 51 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
35 studies in Diabetes Mellitus by Pfizer: 2 open now, 3 under way, 3 of them phase 3. Of 30 finished, 15 (50%) have results posted.
Among the 35 studies in Diabetes Mellitus by Pfizer, this one is the 8th largest by enrollment of the 30 interventional ones that give a count, is the only one that started in 2002, is one of 12 in phase 3, and was the 5th registered.
Pfizer’s Diabetes Mellitus studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 51 studies testing insulin in Diabetes Mellitus, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 35 in Diabetes Mellitus:
This tab as a report to print or save as PDF → With an account.
This study is being done to find out the good and bad effects of inhaled insulin that is used by oral inhalation, to adult males and females with type 2 diabetes mellitus. The other name for this inhaled insulin is Exubera®.
This study included a 2-year comparative treatment period followed by a 6-month follow-up period during which inhaled insulin-treated subjects were switched back to subcutaneous short-acting insulin. After this follow-up period, all eligible subjects entered a comparative extension period that was to last for 5 years. When the comparative portion of the study was terminated, all subjects were requested to return for a final extension follow-up month 3 visit.
Pfizer announced in October 2007 that it would stop marketing Exubera. Nektar, the company from which Pfizer licensed Exubera, announced on April 9, 2008 that it had stopped its search for a new marketing partner. Accordingly, there will be no commercial availability of Exubera. As a result, study A2171029 was terminated on June 9, 2008. Neither safety nor efficacy reasons were the cause of the study termination.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Inhalable short-acting insulin
Drug: Inhaled Insulin
Drug: Subcutaneous insulin
Inhaled insulin with dose adjusted according to premeal blood glucose
Also known as: Exubera
Subcutaneous insulin with dose adjusted according to premeal blood glucose
Change From Month 3 in Forced Expiratory Volume in 1 Second (FEV1)
Change from Month 3: mean of (value of observed FEV1 \[forced expiratory volume in the first second of forced exhalation\] in liters \[L\] at treatment observation minus Month 3 value).
Time frame: Month 3 through extension Month 60
Change From Baseline in FEV1
Change from baseline: mean of (value of observed FEV1 \[L\] at treatment observation minus baseline value).
Time frame: Baseline through extension follow up Month 3
Annual Rate of Change in FEV1
Annual rate of change in FEV1 calculated as slope over time \[visit\] for forced expiratory volume in 1 second measured as liters per year (L/yr).
Time frame: Week -2 through extension follow up Month 3 or end of study
Summary of ≥ 15 % Decliners in FEV1
Number of subjects with a post-baseline FEV1 decrease of ≥ 15 % \[(baseline observed value - visit observed value)/(baseline observed value) \* 100\]; in the absence of an obvious intercurrrent illness, a repeat FEV1 was performed.
Time frame: Month 3 through extension follow up Month 3
Annual Rate of Change in Carbon Monoxide Diffusion Capacity (DLco)
Annual rate of change in DLco calculated as slope over time (visit) measured as milliliters per minute per millimeters of mercury per year (ml/min/mmHg/yr).
Time frame: Week -2 through extension follow up Month 3 or end of study
Change From Baseline in Carbon Monoxide Diffusion Capacity (DLco)
Change from baseline: mean of (value of observed DLco \[milliliters per minute per millimeters of mercury (ml/min/mmHg)\] at treatment observation minus baseline value).
Time frame: Baseline through extension follow up Month 3
Summary of ≥ 20 % Decliners in DLco
Number of subjects with a post-baseline DLco decrease of ≥ 20 % \[(baseline observed value - visit observed value)/(baseline observed value) \* 100\]; in the absence of an obvious intercurrrent illness, a repeat DLco was performed.
Time frame: Month 3 through extension follow up Month 3
Forced Vital Capacity (FVC)
Forced Vital Capacity (FVC) measured in liters (L).
Time frame: Week -3 through extension follow up Month 3 or end of study
Total Lung Capacity (TLC)
Total Lung Capacity measured in liters (L).
Time frame: Baseline through extension follow up Month 3
Change From Baseline in Glycosylated Hemoglobin (HbA1c)
Change from baseline: mean of (value of observed HbA1c \[%\] at treatment observation minus baseline value).
Time frame: Baseline through extension follow up Month 3
Change From Baseline in Fasting Plasma Glucose (FPG)
Change from baseline: mean of (value of observed FPG \[milligrams per deciliter (mg/dL)\] at treatment observation minus baseline value).
Time frame: Baseline through extension follow up Month 3
Change From Baseline in Body Weight
Change from baseline: mean of (value of observed body weight \[kilograms (kg)\] at treatment observation minus baseline value).
Time frame: Baseline through extension follow up Month 3
Total Daily Long-acting Insulin Dose (Unadjusted for Body Weight)
Total daily long-acting insulin dose unadjusted for body weight. Long-acting (units) insulin for inhaled insulin and subcutaneous treatment groups included NPH insulin, Ultralente®, and insulin glargine.
Time frame: Month 3 through extension Month 36
Total Daily Long-acting Insulin (Adjusted for Body Weight)
Total daily dose of long-acting insulin adjusted for body weight (units per kilogram \[kg\]). Long-acting (units) insulin for inhaled insulin and subcutaneous treatment groups included NPH insulin, Ultralente®, and insulin glargine.
Time frame: Month 3 through extension Month 36
Total Daily Short-acting Insulin Dose (Unadjusted for Body Weight)
Total daily dose of short-acting insulin unadjusted for body weight. Short-acting insulin (milligrams \[mg\]) for the inhaled insulin treatment group was inhaled insulin; short-acting insulin (units) for the subcutaneous insulin treatment group included insulin lispro, insulin aspart, and regular insulin.
Time frame: Month 3 through extension Month 36
Total Daily Short-acting Insulin Dose (Adjusted for Body Weight)
Total daily dose of short-acting insulin adjusted for body weight. Short-acting insulin (mg) for the inhaled insulin treatment group was inhaled insulin (mg divided by kg); short-acting insulin (units) for the subcutaneous insulin treatment group included insulin lispro, insulin aspart, and regular insulin (units divided by kg).
Time frame: Month 3 through extension Month 36
Lipid Panel: Total Cholesterol, High Density Lipoprotein, Low Density Lipoprotein, and Triglycerides
Lipid values for total cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL), and triglycerides measured as milligrams per deciliter (mg/dL).
Time frame: Week -4 through Month 24
Hypoglycemic Event Rates
Hypoglycemic event rate; hypoglycemic event identified by characteristic symptoms of hypoglycemia with no blood glucose (BG) check with prompt resolution with food intake, SC glucagon, or intravenous (IV) glucose; characteristic symptoms with BG of 59 mg/dL (3.2 mmol/L) or less with or without symptoms. Crude event rate = total events divided by subject months (elapsed number of months a subject was in the study at each time interval).
Time frame: Month 1 through extension Month 36
Severe Hypoglycemic Event Rates
Severe hypoglycemic event rate; all 3 criteria were met: subject unable to treat self, exhibited at least 1 neurological symptom (memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty awakening, suspected seizure, loss of consciousness); BG measurement ≤49 mg/dL, or not measured but clinical manifestations reversed by oral carbohydrates, SC glucagon, or IV glucose. Crude event rate: total events divided by subject months multiplied by 100 (\[total events/subject months\]\*100). Subjects months: elapsed number of months subject was in study in each time interval.
Time frame: Month 1 through extension Month 36
Cough Questionnaire
Clinician administered 6 question instrument to measure cough frequency (night, day), severity, timing in relation to short-acting insulin dosing, severity related to insulin dosing (SC or inhaled), and productivity of cough; range 0 (indicates no symptoms) to 4 (indicates severe symptoms). Questionnaire administered at Week 0 then if and only if, cough is identified as an adverse event not explained by a concomitant condition, such as an upper respiratory tract infection.
Time frame: Week 0 and if indicated through extension follow up Month 3
Baseline Dyspnea Index (BDI)
Clinician administered instrument to measure the baseline severity of breathlessness (shortness of breath) in symptomatic patients with 3 domains: functional impairment, magnitude of task, and magnitude of effort. BDI score range 0 (very severe impairment) to 4 (no impairment) scaled to a BDI focal score (0-12). Lower score indicates greater impairment.
Time frame: Week -1
Transition Dyspnea Index (TDI)
Clinician administered instrument to measure the baseline severity of breathlessness (shortness of breath) in symptomatic patients with 3 domains: functional impairment, magnitude of task, and magnitude of effort. TDI score range -3 (major deterioration) to +3 (major improvement); sum of all domains yields the TDI focal score (-9 to +9); lower score indicates greater deterioration. Compared to previous scoring to determine deterioration or improvement.
Time frame: Week 4 through extension follow up Month 3 or end of study
High Resolution Computerized Tomography (HRCT) Scan: Within Normal Limits (Yes or No) at Observation When Baseline HRCT Was Within Normal Limits
Number of subjects with Yes or No responses (within normal limits at specified time points = Yes or not within normal limits at specified time points = No) at observation when HRCT of thorax was within normal limits at baseline.
Time frame: Baseline, M12, M24, Ext M6, Ext M18, Ext M36
High Resolution Computerized Tomography (HRCT) Scan: Within Normal Limits (Yes or No) at Observation When Baseline HRCT Was Not Within Normal Limits
Number of subjects with Yes or No responses (within normal limits at specified time points = Yes or not within normal limits at specified time points = No) at observation when HRCT of thorax was not within normal limits at baseline. "No" response at observation further categorized as no significant change (NSC), more abnormal (\> Abn), or less abnormal (\< Abn).
Time frame: Baseline, M12, M24, Ext M6, Ext M18, Ext M36
Insulin Antibodies
Observed values for insulin antibodies measured as micro units per milliliter (microU/mL).
Time frame: Baseline through extension Month 36
| Milestone | Inhaled Insulin (Exubera®) | Subcutaneous Insulin |
|---|---|---|
| Started | 319 | 316 |
| Received treatment | 316 | 311 |
| Completed | 194 | 212 |
| Not completed | 125 | 104 |
| Withdrew: Never received study treatment | 3 | 5 |
| Withdrew: Death | 1 | 3 |
| Withdrew: Adverse event | 27 | 8 |
| Withdrew: Laboratory abnormality | 0 | 1 |
| Withdrew: Lack of efficacy | 13 | 3 |
| Withdrew: Lost to follow-up | 12 | 14 |
| Withdrew: Withdrawal by subject | 44 | 46 |
| Withdrew: Other | 22 | 24 |
| Withdrew: Discontinued in follow up period | 3 | 0 |
Change from Month 3: mean of (value of observed FEV1 \[forced expiratory volume in the first second of forced exhalation\] in liters \[L\] at treatment observation minus Month 3 value).
No measurements were reported for this outcome.
Change from baseline: mean of (value of observed FEV1 \[L\] at treatment observation minus baseline value).
| L | Inhaled Insulin (Exubera®) | Subcutaneous Insulin |
|---|---|---|
| Baseline (n=311, 304) | 2.91 ± 0.68 | 2.93 ± 0.71 |
| Month 3 (M3) (n=290, 291) | -0.06 ± 0.13 | -0.01 ± 0.15 |
| M6 (n=281, 280) | -0.05 ± 0.16 | -0.05 ± 0.17 |
| M9 (n=266, 276) | -0.08 ± 0.17 | -0.07 ± 0.16 |
| M12 (n=259, 263) | -0.09 ± 0.17 | -0.07 ± 0.16 |
| M15 (n=247, 250) | -0.12 ± 0.18 | -0.09 ± 0.17 |
| M18 (n=237, 236) | -0.12 ± 0.18 | -0.10 ± 0.18 |
| M21 (n=232, 233) | -0.13 ± 0.18 | -0.11 ± 0.18 |
| M24 (n=223, 226) | -0.15 ± 0.19 | -0.13 ± 0.18 |
| Follow-up (FU) M1 (n=249, 221) | -0.14 ± 0.18 | -0.14 ± 0.19 |
| FU M3 (n=248, 231) | -0.13 ± 0.21 | -0.14 ± 0.20 |
| FU M6 (n=242, 220) | -0.12 ± 0.20 | -0.15 ± 0.18 |
| Extension (Ext) M1 (n=161, 163) | -0.16 ± 0.20 | -0.16 ± 0.20 |
| Ext M3 (n=157, 158) | -0.19 ± 0.21 | -0.16 ± 0.19 |
| Ext M6 (n=148, 159) | -0.20 ± 0.21 | -0.17 ± 0.20 |
| Ext M9 (n=144, 157) | -0.19 ± 0.21 | -0.16 ± 0.21 |
| Ext M12 (n=144, 157) | -0.20 ± 0.21 | -0.18 ± 0.22 |
| Ext M15 (n=141, 145) | -0.22 ± 0.23 | -0.21 ± 0.20 |
| Ext M18 (n=135, 139) | -0.22 ± 0.23 | -0.21 ± 0.22 |
| Ext M21 (n=132, 143) | -0.23 ± 0.24 | -0.21 ± 0.21 |
| Ext M24 (n=125, 131) | -0.24 ± 0.24 | -0.23 ± 0.22 |
| Ext M27 (n=124, 125) | -0.25 ± 0.23 | -0.24 ± 0.22 |
| Ext M30 (n=125, 126) | -0.24 ± 0.22 | -0.23 ± 0.23 |
| Ext M33 (n=98, 113) | -0.24 ± 0.24 | -0.24 ± 0.22 |
| Ext M36 (n=54, 60) | -0.25 ± 0.18 | -0.28 ± 0.17 |
| Ext M36 [LOCF] (n=171, 169) | -0.24 ± 0.24 | -0.24 ± 0.21 |
| Ext FU M3 (n=119, 115) | -0.24 ± 0.21 | -0.25 ± 0.20 |
Annual rate of change in FEV1 calculated as slope over time \[visit\] for forced expiratory volume in 1 second measured as liters per year (L/yr).
No measurements were reported for this outcome.
Number of subjects with a post-baseline FEV1 decrease of ≥ 15 % \[(baseline observed value - visit observed value)/(baseline observed value) \* 100\]; in the absence of an obvious intercurrrent illness, a repeat FEV1 was performed.
| participants | Inhaled Insulin (Exubera®) | Subcutaneous Insulin |
|---|---|---|
| M3 (n=290, 291) | 2 | 2 |
| M6 (n=281, 280) | 3 | 4 |
| M9 (n=266, 276) | 7 | 5 |
| M12 (n=259, 263) | 7 | 4 |
| M15 (n=247, 250) | 13 | 6 |
| M18 (n=237, 236) | 10 | 8 |
| M21 (n=232, 233) | 12 | 8 |
| M24 (n=223, 226) | 14 | 13 |
| FU M1 (n=249, 221) | 11 | 7 |
| FU M3 (n=248, 231) | 16 | 15 |
| FU M6 (n=242, 220) | 13 | 11 |
| Ext M1 (n=161, 163) | 12 | 6 |
| Ext M3 (n=157, 158) | 12 | 5 |
| Ext M6 (n=148, 159) | 14 | 8 |
| Ext M9 (n=144, 157) | 11 | 10 |
| Ext M12 (n=144, 157) | 19 | 13 |
| Ext M15 (n=141, 145) | 15 | 11 |
| Ext M18 (n=135, 139) | 17 | 18 |
| Ext M21 (n=132, 143) | 22 | 11 |
| Ext M24 (n=125, 131) | 22 | 16 |
| Ext M27 (n=124, 125) | 18 | 14 |
| Ext M30 (n=125, 126) | 20 | 18 |
| Ext M33 (n=98, 113) | 10 | 12 |
| Ext M36 (n=54, 60) | 5 | 6 |
| Ext FU M3 (n=119, 115) | 14 | 19 |
Annual rate of change in DLco calculated as slope over time (visit) measured as milliliters per minute per millimeters of mercury per year (ml/min/mmHg/yr).
No measurements were reported for this outcome.
Forced Vital Capacity (FVC) measured in liters (L).
No measurements were reported for this outcome.
Total Lung Capacity measured in liters (L).
No measurements were reported for this outcome.
Change from baseline: mean of (value of observed HbA1c \[%\] at treatment observation minus baseline value).
| percent | Inhaled Insulin (Exubera®) | Subcutaneous Insulin |
|---|---|---|
| Baseline (n=315, 303) | 7.66 ± 1.12 | 7.77 ± 1.12 |
| Week 6 (W6) (n=291, 280) | -0.64 ± 0.67 | -0.60 ± 0.70 |
| M3 (n=296, 291) | -0.80 ± 0.86 | -0.73 ± 0.89 |
| M6 (n=284, 287) | -0.67 ± 0.94 | -0.68 ± 1.00 |
| M9 (n=270, 280) | -0.56 ± 0.98 | -0.61 ± 0.93 |
| M12 (n=261, 263) | -0.45 ± 0.94 | -0.58 ± 1.00 |
| M15(n=252, 258) | -0.43 ± 1.00 | -0.51 ± 1.00 |
| M18(n=244, 241) | -0.42 ± 1.02 | -0.53 ± 1.06 |
| M21 (n=236, 238) | -0.43 ± 1.04 | -0.52 ± 1.02 |
| M24 (n=226, 234) | -0.35 ± 1.09 | -0.48 ± 1.13 |
| FU M3 (n=225, 226) | -0.41 ± 1.04 | -0.44 ± 1.06 |
| FU M6 (n=230, 230) | -0.27 ± 1.12 | -0.31 ± 1.06 |
| Ext M1 (n=167, 162) | -0.41 ± 1.16 | -0.40 ± 1.05 |
| Ext M3 (n=164, 162) | -0.33 ± 1.19 | -0.42 ± 1.05 |
| Ext M6 (n=157, 163) | -0.26 ± 1.11 | -0.40 ± 1.10 |
| Ext M9 (n=152, 157) | -0.11 ± 1.15 | -0.26 ± 1.13 |
| Ext M12 (n=150, 157) | -0.08 ± 1.19 | -0.17 ± 1.16 |
| Ext M15(n=146, 151) | -0.17 ± 1.30 | -0.25 ± 1.15 |
| Ext M18 (n=145, 145) | -0.20 ± 1.19 | -0.29 ± 1.17 |
| Ext M21(n=137, 147) | -0.13 ± 1.16 | -0.20 ± 1.20 |
| Ext M24 (n=131, 137) | -0.18 ± 1.21 | -0.23 ± 1.11 |
| Ext M27(n=129, 132) | -0.18 ± 1.13 | -0.28 ± 1.20 |
| Ext M30 (n=129, 129) | -0.20 ± 1.19 | -0.30 ± 1.19 |
| Ext M33(n=104, 116) | 8.54 ± 88.44 | -0.18 ± 1.17 |
| Ext M36 (n=55, 64) | -0.20 ± 1.15 | -0.30 ± 1.18 |
| Ext FU M3 (n=117, 116) | -0.11 ± 1.40 | -0.17 ± 1.28 |
Change from baseline: mean of (value of observed FPG \[milligrams per deciliter (mg/dL)\] at treatment observation minus baseline value).
| mg/dL | Inhaled Insulin (Exubera®) | Subcutaneous Insulin |
|---|---|---|
| Baseline (n=315, 303) | 158.13 ± 42.71 | 154.53 ± 41.51 |
| W6 (n=282, 276) | -23.36 ± 51.69 | -12.55 ± 50.46 |
| M3 (n=294, 290) | -26.38 ± 52.72 | -12.77 ± 54.93 |
| M6 (n=281, 285) | -25.21 ± 53.48 | -9.05 ± 68.42 |
| M9 (n=267, 279) | -26.68 ± 54.95 | -10.41 ± 56.42 |
| M12 (n=260, 263) | -20.55 ± 59.68 | -7.60 ± 60.03 |
| M15(n=253, 255) | -21.37 ± 54.53 | -8.82 ± 55.57 |
| M18(n=242, 238) | -24.52 ± 54.50 | -7.69 ± 58.47 |
| M21(n=232, 237) | -25.95 ± 53.06 | -13.14 ± 54.66 |
| M24 (n=226, 232) | -24.02 ± 54.45 | -8.91 ± 65.24 |
| FU M3 (n=5, 4) | -22.60 ± 44.65 | -4.08 ± 32.08 |
| FU M6 (n=161, 156) | -2.85 ± 66.18 | -1.56 ± 71.72 |
| Ext M1 (n=165, 162) | -17.91 ± 60.96 | -7.34 ± 60.98 |
| Ext M3 (n=162, 159) | -18.16 ± 66.59 | -9.29 ± 62.50 |
| Ext M6 (n=152, 161) | -15.65 ± 67.18 | -4.34 ± 61.96 |
| Ext M9 (n=149, 155) | -13.99 ± 61.68 | -6.06 ± 60.86 |
| Ext M12 (n=148, 155) | -12.53 ± 72.25 | -4.98 ± 62.92 |
| Ext M15(n=143, 143) | -6.88 ± 68.85 | -4.23 ± 65.21 |
| Ext M18 (n=136, 138) | -17.23 ± 65.97 | -10.32 ± 63.11 |
| Ext M21(n=132, 144) | -12.86 ± 63.98 | -6.53 ± 64.09 |
| Ext M24 (n=129, 136) | -14.45 ± 61.65 | -3.47 ± 68.57 |
| Ext M27 (n=128, 129) | -21.68 ± 58.35 | -3.76 ± 63.31 |
| Ext M30 (n=127, 130) | -11.80 ± 62.82 | -6.40 ± 61.47 |
| Ext M33(n=103, 115) | -16.26 ± 63.44 | -7.35 ± 66.21 |
| Ext M36 (n=55, 64) | -28.61 ± 65.99 | -13.35 ± 53.97 |
| Ext FU M3 (n=115, 118) | -2.87 ± 81.19 | 1.88 ± 64.94 |
Change from baseline: mean of (value of observed body weight \[kilograms (kg)\] at treatment observation minus baseline value).
| kg | Inhaled Insulin (Exubera®) | Subcutaneous Insulin |
|---|---|---|
| Baseline (n=314, 302) | 87.18 ± 14.75 | 88.31 ± 15.50 |
| W4 (n=280, 270) | 0.63 ± 2.11 | 0.83 ± 1.86 |
| W8 (n=289, 281) | 1.07 ± 2.41 | 1.00 ± 2.31 |
| M3 (n=288, 290) | 1.08 ± 2.75 | 1.13 ± 2.55 |
| W18(n=280, 285) | 1.33 ± 3.13 | 1.76 ± 3.03 |
| M6 (n=276, 277) | 1.15 ± 3.59 | 1.89 ± 3.53 |
| M9 (n=269, 274) | 1.50 ± 3.95 | 2.15 ± 3.90 |
| M12 (n=259, 264) | 1.75 ± 4.29 | 2.37 ± 4.34 |
| M15(n=247, 249) | 1.88 ± 4.33 | 2.62 ± 4.49 |
| M18(n=237, 235) | 1.79 ± 4.53 | 2.93 ± 4.85 |
| M21(n=232, 232) | 1.99 ± 4.56 | 3.04 ± 5.04 |
| M24 (n=223, 226) | 2.04 ± 4.86 | 3.36 ± 5.16 |
| FU M3 (n=249, 231) | 2.32 ± 5.25 | 3.63 ± 5.34 |
| FU M6 (n=243, 218) | 2.38 ± 5.34 | 4.09 ± 7.70 |
| Ext M1 (n=161, 162) | 2.87 ± 5.48 | 3.75 ± 5.58 |
| Ext M3 (n=157, 157) | 2.83 ± 4.78 | 4.14 ± 5.69 |
| Ext M6 (n=148, 159) | 3.15 ± 5.70 | 4.01 ± 6.07 |
| Ext M9 (n=144, 156) | 2.95 ± 5.95 | 3.89 ± 5.87 |
| Ext M12 (n=144, 156) | 2.96 ± 6.00 | 4.19 ± 6.12 |
| Ext M15 (n=142, 145) | 3.12 ± 5.91 | 4.54 ± 6.26 |
| Ext M18 (n=135, 139) | 3.33 ± 9.20 | 4.46 ± 6.12 |
| Ext M21(n=132, 143) | 2.79 ± 6.90 | 5.01 ± 8.37 |
| Ext M24 (n=126, 131) | 2.94 ± 6.98 | 4.57 ± 6.37 |
| Ext M27(n=125, 125) | 2.99 ± 6.94 | 5.58 ± 9.62 |
| Ext M30 (n=125, 126) | 3.39 ± 6.43 | 4.78 ± 6.96 |
| Ext M33(n=99, 113) | 2.77 ± 6.33 | 5.22 ± 7.21 |
| Ext M36 (n=54, 60) | 2.48 ± 6.61 | 5.28 ± 7.09 |
| Ext FU M3 (n=119, 115) | 2.74 ± 6.90 | 4.44 ± 6.87 |
Total daily long-acting insulin dose unadjusted for body weight. Long-acting (units) insulin for inhaled insulin and subcutaneous treatment groups included NPH insulin, Ultralente®, and insulin glargine.
| units | Inhaled Insulin (Exubera®) | Subcutaneous Insulin |
|---|---|---|
| M3 (n=301, 298) | 44.10 ± 25.60 | 47.98 ± 25.06 |
| M6 (n=289, 291) | 44.03 ± 26.27 | 47.31 ± 25.47 |
| M9 (n=275, 284) | 43.64 ± 26.17 | 48.11 ± 26.02 |
| M12 (n=266, 270) | 44.62 ± 27.43 | 48.01 ± 26.02 |
| M15 (n=258, 260) | 45.02 ± 27.76 | 48.37 ± 26.48 |
| M18 (n=243, 242) | 46.07 ± 27.77 | 48.93 ± 27.60 |
| M21 (n=240, 240) | 46.67 ± 29.06 | 49.84 ± 28.73 |
| M24 (n=229, 237) | 46.62 ± 28.55 | 50.34 ± 29.31 |
| Ext M1 (n=167, 164) | 45.29 ± 28.00 | 51.29 ± 28.45 |
| Ext M3 (n=165, 162) | 45.76 ± 28.61 | 51.62 ± 28.71 |
| Ext M6 (n=159, 164) | 45.89 ± 28.61 | 52.18 ± 28.85 |
| Ext M9 (n=156, 158) | 46.51 ± 29.34 | 52.32 ± 28.89 |
| Ext M12 (n=151, 158) | 46.52 ± 29.84 | 51.72 ± 29.06 |
| Ext M15 (n=148, 149) | 46.39 ± 30.12 | 52.92 ± 29.83 |
| Ext M18 (n=145, 145) | 46.31 ± 31.17 | 52.37 ± 29.78 |
| Ext M21 (n=137, 148) | 46.49 ± 31.17 | 52.68 ± 29.40 |
| Ext M24 (n=131, 137) | 47.21 ± 32.42 | 52.18 ± 30.33 |
| Ext M27 (n=132, 133) | 48.13 ± 32.76 | 52.42 ± 29.87 |
| Ext M30 (n=131, 130) | 48.13 ± 33.41 | 53.22 ± 29.85 |
| Ext M33 (n=104, 116) | 48.38 ± 32.47 | 51.93 ± 30.65 |
| Ext M36 (n=56, 65) | 46.42 ± 31.91 | 53.47 ± 28.96 |
Total daily dose of long-acting insulin adjusted for body weight (units per kilogram \[kg\]). Long-acting (units) insulin for inhaled insulin and subcutaneous treatment groups included NPH insulin, Ultralente®, and insulin glargine.
| units/kg | Inhaled Insulin (Exubera®) | Subcutaneous Insulin |
|---|---|---|
| M3 (n=301, 298) | 0.51 ± 0.29 | 0.54 ± 0.27 |
| M6 (n=289, 291) | 0.50 ± 0.29 | 0.54 ± 0.28 |
| M9 (n=275, 284) | 0.50 ± 0.29 | 0.55 ± 0.29 |
| M12 (n=266, 270) | 0.51 ± 0.30 | 0.55 ± 0.29 |
| M15 (n=258, 260) | 0.52 ± 0.31 | 0.56 ± 0.30 |
| M18 (n=243, 242) | 0.53 ± 0.31 | 0.57 ± 0.31 |
| M21 (n=240, 240) | 0.53 ± 0.32 | 0.57 ± 0.32 |
| M24 (n=229, 237) | 0.54 ± 0.32 | 0.58 ± 0.32 |
| Ext M1 (n=167, 164) | 0.53 ± 0.33 | 0.59 ± 0.31 |
| Ext M3 (n=165, 162) | 0.53 ± 0.34 | 0.59 ± 0.31 |
| Ext M6 (n=159, 164) | 0.54 ± 0.34 | 0.60 ± 0.31 |
| Ext M9 (n=156, 158) | 0.54 ± 0.35 | 0.60 ± 0.31 |
| Ext M12 (n=151, 158) | 0.54 ± 0.36 | 0.60 ± 0.32 |
| Ext M15 (n=148, 149) | 0.54 ± 0.36 | 0.61 ± 0.32 |
| Ext M18 (n=145, 145) | 0.54 ± 0.37 | 0.61 ± 0.32 |
| Ext M21 (n=137, 148) | 0.54 ± 0.37 | 0.61 ± 0.32 |
| Ext M24 (n=131, 137) | 0.55 ± 0.39 | 0.61 ± 0.34 |
| Ext M27 (n=132, 133) | 0.56 ± 0.39 | 0.61 ± 0.33 |
| Ext M30 (n=131, 130) | 0.56 ± 0.41 | 0.62 ± 0.33 |
| Ext M33 (n=104, 116) | 0.56 ± 0.37 | 0.61 ± 0.34 |
| Ext M36 (n=56, 65) | 0.53 ± 0.37 | 0.61 ± 0.31 |
Total daily dose of short-acting insulin unadjusted for body weight. Short-acting insulin (milligrams \[mg\]) for the inhaled insulin treatment group was inhaled insulin; short-acting insulin (units) for the subcutaneous insulin treatment group included insulin lispro, insulin aspart, and regular insulin.
| mg, units | Inhaled Insulin (Exubera®) (mg) | Subcutaneous Insulin (Units) |
|---|---|---|
| M3 (n=302, 299) | 12.66 ± 6.80 | 31.15 ± 18.75 |
| M6 (n=290, 292) | 13.18 ± 6.90 | 31.73 ± 19.08 |
| M9 (n=275, 285) | 13.57 ± 7.57 | 31.58 ± 18.89 |
| M12 (n=266, 270) | 14.40 ± 7.90 | 31.94 ± 19.29 |
| M15 (n=258, 261) | 14.70 ± 8.06 | 31.88 ± 19.37 |
| M18 (n=245, 242) | 14.91 ± 8.41 | 32.79 ± 20.70 |
| M21 (n=240, 242) | 15.09 ± 8.55 | 33.18 ± 20.92 |
| M24 (n=229, 238) | 15.43 ± 8.65 | 34.04 ± 21.84 |
| Ext M1 (n=167, 164) | 13.89 ± 8.47 | 34.52 ± 24.52 |
| Ext M3 (n=165, 163) | 14.62 ± 9.18 | 35.29 ± 23.19 |
| Ext M6 (n=159, 165) | 14.62 ± 9.16 | 35.43 ± 24.80 |
| Ext M9 (n=156, 161) | 14.82 ± 9.10 | 35.68 ± 24.72 |
| Ext M12 (n=151, 160) | 15.42 ± 9.81 | 36.56 ± 26.34 |
| Ext M15 (n=148, 151) | 15.48 ± 9.90 | 36.27 ± 25.51 |
| Ext M18 (n=145, 146) | 15.57 ± 9.93 | 37.37 ± 26.29 |
| Ext M21 (n=138, 149) | 15.94 ± 10.41 | 36.80 ± 27.09 |
| Ext M24 (n=131, 138) | 15.46 ± 9.70 | 38.51 ± 29.06 |
| Ext M27 (n=132, 134) | 16.25 ± 10.30 | 38.54 ± 28.13 |
| Ext M30 (n=131, 131) | 16.56 ± 10.63 | 39.01 ± 28.66 |
| Ext M33 (n=105, 117) | 16.51 ± 10.43 | 40.33 ± 30.81 |
| Ext M36 (n=56, 66) | 17.25 ± 11.30 | 42.34 ± 28.72 |
Total daily dose of short-acting insulin adjusted for body weight. Short-acting insulin (mg) for the inhaled insulin treatment group was inhaled insulin (mg divided by kg); short-acting insulin (units) for the subcutaneous insulin treatment group included insulin lispro, insulin aspart, and regular insulin (units divided by kg).
| mg/kg, units/kg | Inhaled Insulin (Exubera®) (mg) | Subcutaneous Insulin (Units) |
|---|---|---|
| M3 (n=302, 299) | 0.15 ± 0.07 | 0.36 ± 0.22 |
| M6 (n=290, 292) | 0.15 ± 0.08 | 0.36 ± 0.22 |
| M9 (n=275, 285) | 0.16 ± 0.08 | 0.36 ± 0.22 |
| M12 (n=266, 270) | 0.17 ± 0.09 | 0.37 ± 0.23 |
| M15 (n=258, 261) | 0.17 ± 0.09 | 0.37 ± 0.24 |
| M18 (n=245, 242) | 0.17 ± 0.09 | 0.38 ± 0.25 |
| M21 (n=240, 242) | 0.17 ± 0.09 | 0.39 ± 0.26 |
| M24 (n=229, 238) | 0.18 ± 0.10 | 0.40 ± 0.27 |
| Ext M1 (n=167, 164) | 0.16 ± 0.09 | 0.40 ± 0.30 |
| Ext M3 (n=165, 163) | 0.17 ± 0.10 | 0.41 ± 0.26 |
| Ext M6 (n=159, 165) | 0.17 ± 0.10 | 0.41 ± 0.30 |
| Ext M9 (n=156, 161) | 0.17 ± 0.10 | 0.42 ± 0.30 |
| Ext M12 (n=151, 160) | 0.18 ± 0.11 | 0.43 ± 0.32 |
| Ext M15 (n=148, 151) | 0.18 ± 0.11 | 0.42 ± 0.31 |
| Ext M18 (n=145, 146) | 0.18 ± 0.11 | 0.44 ± 0.32 |
| Ext M21 (n=138, 149) | 0.18 ± 0.11 | 0.43 ± 0.33 |
| Ext M24 (n=131, 138) | 0.18 ± 0.10 | 0.45 ± 0.35 |
| Ext M27 (n=132, 134) | 0.19 ± 0.11 | 0.45 ± 0.34 |
| Ext M30 (n=131, 131) | 0.19 ± 0.12 | 0.46 ± 0.34 |
| Ext M33 (n=105, 117) | 0.19 ± 0.11 | 0.47 ± 0.36 |
| Ext M36 (n=56, 66) | 0.19 ± 0.12 | 0.48 ± 0.31 |
Lipid values for total cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL), and triglycerides measured as milligrams per deciliter (mg/dL).
No measurements were reported for this outcome.
Change from baseline: mean of (value of observed DLco \[milliliters per minute per millimeters of mercury (ml/min/mmHg)\] at treatment observation minus baseline value).
| ml/min/mmHg | Inhaled Insulin (Exubera®) | Subcutaneous Insulin |
|---|---|---|
| Baseline (n=308, 303) | 24.13 ± 5.54 | 23.97 ± 5.72 |
| M3 (n=289, 290) | -0.57 ± 1.60 | -0.32 ± 1.62 |
| M6 (n=278, 280) | -0.56 ± 1.62 | -0.44 ± 1.73 |
| M9 (n=266, 272) | -0.67 ± 1.78 | -0.72 ± 1.77 |
| M12 (n=258, 263) | -0.72 ± 1.86 | -0.41 ± 1.87 |
| M15 (n=246, 248) | -0.81 ± 1.83 | -0.56 ± 1.96 |
| M18 (n=237, 232) | -0.86 ± 1.95 | -0.65 ± 1.92 |
| M21 (n=231, 231) | -0.89 ± 1.98 | -0.67 ± 1.92 |
| M24 (n=221, 223) | -0.74 ± 2.10 | -0.81 ± 2.06 |
| FU M1 (n=247, 220) | -0.46 ± 2.05 | -1.02 ± 2.01 |
| FU M3 (n=247, 231) | -0.58 ± 2.07 | -0.90 ± 2.15 |
| FU M6 (n=241, 219) | -0.64 ± 2.15 | -0.95 ± 2.11 |
| Ext M1 (n=159, 161) | -1.01 ± 2.08 | -1.09 ± 2.15 |
| Ext M3 (n=157, 157) | -1.07 ± 2.10 | -1.16 ± 2.45 |
| Ext M6 (n=148, 157) | -1.48 ± 1.87 | -1.26 ± 2.38 |
| Ext M9 (n=143, 155) | -1.15 ± 2.31 | -1.36 ± 2.54 |
| Ext M12 (n=141, 155) | -1.49 ± 2.22 | -1.59 ± 2.38 |
| Ext M15 (n=141, 142) | -1.49 ± 2.25 | -1.46 ± 2.41 |
| Ext M18 (n=132, 138) | -1.54 ± 2.25 | -1.63 ± 2.21 |
| Ext M21 (n=129, 142) | -1.33 ± 2.45 | -1.64 ± 2.45 |
| Ext M24 (n=124, 130) | -1.39 ± 2.27 | -1.46 ± 2.43 |
| Ext M27 (n=123, 124) | -1.35 ± 2.48 | -1.44 ± 2.41 |
| Ext M30 (n=124, 125) | -1.75 ± 2.13 | -1.62 ± 2.55 |
| Ext M33 (n=98, 113) | -1.47 ± 2.05 | -1.61 ± 2.25 |
| Ext M36 (n=52, 60) | -1.22 ± 2.16 | -1.87 ± 2.23 |
| Ext M36 [LOCF] (n=171, 169) | -1.39 ± 2.31 | -1.77 ± 2.46 |
| Ext FU M3 (n=118, 114) | -1.12 ± 2.15 | -1.69 ± 2.56 |
Number of subjects with a post-baseline DLco decrease of ≥ 20 % \[(baseline observed value - visit observed value)/(baseline observed value) \* 100\]; in the absence of an obvious intercurrrent illness, a repeat DLco was performed.
| participants | Inhaled Insulin (Exubera®) | Subcutaneous Insulin |
|---|---|---|
| M3 (n=289, 290) | 0 | 2 |
| M6 (n=278, 280) | 1 | 2 |
| M9 (n=266, 272) | 0 | 3 |
| M12 (n=258, 263) | 4 | 3 |
| M15 (n=246, 248) | 1 | 2 |
| M18(n=237, 232) | 2 | 5 |
| M21 (n=231, 231) | 0 | 3 |
| M24 (n=221, 223) | 4 | 5 |
| FU M1 (n=247, 220) | 2 | 4 |
| FU M3 (n=247, 231) | 3 | 6 |
| FU M6 (n=241, 219) | 5 | 5 |
| Ext M1 (n=159, 161) | 3 | 3 |
| Ext M3 (n=157, 157) | 3 | 8 |
| Ext M6 (n=148, 157) | 4 | 6 |
| Ext M9 (n=143, 155) | 4 | 7 |
| Ext M12 (n=141, 155) | 8 | 9 |
| Ext M15(n=141, 142) | 4 | 6 |
| Ext M18 (n=132, 138) | 6 | 7 |
| Ext M21(n=129, 142) | 4 | 8 |
| Ext M24 (n=124, 130) | 5 | 7 |
| Ext M27(n=123, 124) | 7 | 8 |
| Ext M30 (n=124, 125) | 7 | 11 |
| Ext M33(n=98, 113) | 1 | 4 |
| Ext M36 (n=52, 60) | 2 | 3 |
| Ext FU M3 (n=118, 114) | 6 | 10 |
Hypoglycemic event rate; hypoglycemic event identified by characteristic symptoms of hypoglycemia with no blood glucose (BG) check with prompt resolution with food intake, SC glucagon, or intravenous (IV) glucose; characteristic symptoms with BG of 59 mg/dL (3.2 mmol/L) or less with or without symptoms. Crude event rate = total events divided by subject months (elapsed number of months a subject was in the study at each time interval).
| event rate (events/subject months) | Inhaled Insulin (Exubera®) | Subcutaneous Insulin |
|---|---|---|
| M1 (n=315, 303) | 1.63 | 1.80 |
| M2 (n=307, 302) | 1.40 | 1.60 |
| M3 (n=297, 298) | 1.22 | 1.65 |
| M4 (n=289, 295) | 1.10 | 1.64 |
| M5 (n=284, 293) | 0.95 | 1.28 |
| M6 (n=283, 290) | 0.98 | 1.09 |
| M7 (n=280, 289) | 0.80 | 1.12 |
| M8 (n=276, 288) | 0.82 | 0.94 |
| M9 (n=275, 287) | 0.71 | 0.86 |
| M10 (n=273, 285) | 0.72 | 0.93 |
| M11 (n=267, 274) | 0.68 | 0.79 |
| M12 (n=264, 274) | 0.72 | 0.94 |
| M13 (n=263, 269) | 0.71 | 0.82 |
| M14 (n=260, 265) | 0.62 | 0.87 |
| M15 (n=256, 265) | 0.64 | 0.78 |
| M16 (n=254, 261) | 0.68 | 0.97 |
| M17 (n=252, 257) | 0.53 | 0.82 |
| M18 (n=246, 253) | 0.61 | 0.95 |
| M19 (n=245, 252) | 0.59 | 0.78 |
| M20 (n=242, 249) | 0.62 | 0.73 |
| M21 (n=241, 246) | 0.57 | 0.65 |
| M22 (n=236, 244) | 0.44 | 0.72 |
| M23 (n=236, 241) | 0.41 | 0.82 |
| M24 (n=229, 232) | 0.45 | 0.66 |
| Ext M1 (n=172, 169) | 1.16 | 1.16 |
| Ext M2 (n=171, 169) | 1.10 | 1.33 |
| Ext M3 (n=169, 169) | 1.02 | 1.12 |
| Ext M4 (n=167, 169) | 0.87 | 1.44 |
| Ext M5 (n=165, 168) | 0.91 | 1.18 |
| Ext M6 (n=162, 167) | 0.87 | 1.20 |
| Ext M7 (n=161, 167) | 1.10 | 1.41 |
| Ext M8 (n=158, 164) | 0.82 | 1.34 |
| Ext M9 (n=158, 164) | 0.56 | 1.25 |
| Ext M10 (n=156, 164) | 0.99 | 1.11 |
| Ext M11 (n=153, 164) | 0.70 | 0.92 |
| Ext M12 (n=152, 162) | 1.26 | 1.25 |
| Ext M13 (n=152, 160) | 1.07 | 1.14 |
| Ext M14 (n=151, 159) | 0.95 | 1.01 |
| Ext M15 (n=149, 156) | 0.86 | 1.25 |
| Ext M16 (n=149, 156) | 0.99 | 1.23 |
| Ext M17 (n=148, 154) | 1.20 | 1.01 |
| Ext M18 (n=146, 154) | 1.08 | 1.05 |
| Ext M19 (n=143, 152) | 1.25 | 1.21 |
| Ext M20 (n=142, 152) | 1.20 | 1.08 |
| Ext M21 (n=141, 151) | 0.78 | 1.15 |
| Ext M22 (n=141, 149) | 0.79 | 1.08 |
| Ext M23 (n=139, 149) | 0.82 | 1.06 |
| Ext M24 (n=138, 147) | 0.88 | 1.11 |
| Ext M25 (n=137, 146) | 0.73 | 1.22 |
| Ext M26 (n=137, 145) | 0.68 | 1.25 |
| Ext M27 (n=137, 141) | 0.62 | 1.04 |
| Ext M28 (n=135, 137) | 0.68 | 0.87 |
| Ext M29 (n=135, 137) | 0.81 | 0.91 |
| Ext M30 (n=133, 137) | 0.64 | 0.87 |
| Ext M31 (n=124, 133) | 0.67 | 1.32 |
| Ext M32 (n=117, 125) | 0.82 | 0.81 |
| Ext M33 (n=100, 117) | 0.55 | 0.89 |
| Ext M34 (n=84, 90) | 0.64 | 0.57 |
| Ext M35 (n=66, 78) | 0.63 | 0.80 |
| Ext M36 (n=51, 60) | 0.72 | 0.47 |
| Overall comparative (n=315, 303) | 0.95 | 1.19 |
| Overall extension (n=172, 169) | 0.89 | 1.10 |
Severe hypoglycemic event rate; all 3 criteria were met: subject unable to treat self, exhibited at least 1 neurological symptom (memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty awakening, suspected seizure, loss of consciousness); BG measurement ≤49 mg/dL, or not measured but clinical manifestations reversed by oral carbohydrates, SC glucagon, or IV glucose. Crude event rate: total events divided by subject months multiplied by 100 (\[total events/subject months\]\*100). Subjects months: elapsed number of months subject was in study in each time interval.
| event rate (events/subject months*100) | Inhaled Insulin (Exubera®) | Subcutaneous Insulin |
|---|---|---|
| M1 (n=315, 303) | 0.98 | 0.67 |
| M2 (n=307, 302) | 0.34 | 0.34 |
| M3 (n=297, 298) | 0.69 | 0.34 |
| M4 (n=289, 295) | 0.35 | 1.38 |
| M5 (n=284, 293) | 0.36 | 1.74 |
| M6 (n=283, 290) | 0.72 | 2.10 |
| M7 (n=280, 289) | 0.00 | 0.70 |
| M8 (n=276, 288) | 0.37 | 0.70 |
| M9 (n=275, 287) | 0.74 | 0.35 |
| M10 (n=273, 285) | 0.00 | 0.36 |
| M11 (n=267, 274) | 0.38 | 0.37 |
| M12 (n=264, 274) | 0.76 | 0.37 |
| M13 (n=263, 269) | 0.77 | 0.76 |
| M14 (n=260, 265) | 0.78 | 0.38 |
| M15 (n=256, 265) | 0.79 | 0.77 |
| M16 (n=254, 261) | 0.00 | 0.00 |
| M17 (n=252, 257) | 0.00 | 0.40 |
| M18 (n=246, 253) | 0.00 | 0.40 |
| M19 (n=245, 252) | 0.41 | 0.00 |
| M20 (n=242, 249) | 0.42 | 0.00 |
| M21 (n=241, 246) | 0.00 | 0.00 |
| M22 (n=236, 244) | 0.00 | 0.00 |
| M23 (n=236, 241) | 0.00 | 0.85 |
| M24 (n=229, 232) | 0.00 | 0.00 |
| Ext M1 (n=172, 169 | 0.95 | 0.93 |
| Ext M2 (n=171, 169) | 0.00 | 1.87 |
| Ext M3 (n=169, 169) | 1.92 | 0.94 |
| Ext M4 (n=167, 169) | 1.92 | 0.00 |
| Ext M5 (n=165, 168) | 0.00 | 0.00 |
| Ext M6 (n=162, 167) | 0.00 | 0.94 |
| Ext M7 (n=161, 167) | 0.00 | 1.90 |
| Ext M8 (n=158, 164) | 0.00 | 0.00 |
| Ext M9 (n=158, 164) | 0.00 | 2.86 |
| Ext M10 (n=156, 164) | 0.00 | 3.81 |
| Ext M11 (n=153, 164) | 0.00 | 3.86 |
| Ext M12 (n=152, 162) | 0.98 | 3.91 |
| Ext M13 (n=152, 160) | 0.00 | 0.98 |
| Ext M14 (n=151, 159) | 0.00 | 1.96 |
| Ext M15 (n=149, 156) | 1.00 | 0.00 |
| Ext M16 (n=149, 156) | 1.00 | 1.96 |
| Ext M17 (n=148, 154) | 1.00 | 0.99 |
| Ext M18 (n=146, 154) | 1.01 | 0.00 |
| Ext M19 (n=143, 152) | 1.03 | 0.99 |
| Ext M20 (n=142, 152) | 4.16 | 0.99 |
| Ext M21 (n=141, 151) | 0.00 | 0.00 |
| Ext M22 (n=141, 149) | 0.00 | 1.00 |
| Ext M23 (n=139, 149) | 0.00 | 0.00 |
| Ext M24 (n=138, 147) | 1.06 | 2.02 |
| Ext M25 (n=137, 146) | 0.00 | 1.01 |
| Ext M26 (n=137, 145) | 0.00 | 0.00 |
| Ext M27 (n=137, 141) | 1.07 | 0.00 |
| Ext M28 (n=135, 137) | 0.00 | 0.00 |
| Ext M29 (n=135, 137) | 0.00 | 1.06 |
| Ext M30 (n=133, 137) | 0.00 | 0.00 |
| Ext M31 (n=124, 133) | 0.00 | 1.15 |
| Ext M32 (n=117, 125) | 0.00 | 3.58 |
| Ext M33 (n=100, 117) | 0.00 | 0.00 |
| Ext M34 (n=84, 90) | 0.00 | 1.89 |
| Ext M35 (n=66, 78) | 0.00 | 0.00 |
| Ext M36 (n=51, 60) | 0.00 | 0.82 |
| Overall comparative (n=315, 303) | 0.45 | 0.65 |
| Overall extension (n=172, 169) | 0.50 | 1.17 |
Clinician administered 6 question instrument to measure cough frequency (night, day), severity, timing in relation to short-acting insulin dosing, severity related to insulin dosing (SC or inhaled), and productivity of cough; range 0 (indicates no symptoms) to 4 (indicates severe symptoms). Questionnaire administered at Week 0 then if and only if, cough is identified as an adverse event not explained by a concomitant condition, such as an upper respiratory tract infection.
No measurements were reported for this outcome.
Clinician administered instrument to measure the baseline severity of breathlessness (shortness of breath) in symptomatic patients with 3 domains: functional impairment, magnitude of task, and magnitude of effort. BDI score range 0 (very severe impairment) to 4 (no impairment) scaled to a BDI focal score (0-12). Lower score indicates greater impairment.
No measurements were reported for this outcome.
Clinician administered instrument to measure the baseline severity of breathlessness (shortness of breath) in symptomatic patients with 3 domains: functional impairment, magnitude of task, and magnitude of effort. TDI score range -3 (major deterioration) to +3 (major improvement); sum of all domains yields the TDI focal score (-9 to +9); lower score indicates greater deterioration. Compared to previous scoring to determine deterioration or improvement.
No measurements were reported for this outcome.
Number of subjects with Yes or No responses (within normal limits at specified time points = Yes or not within normal limits at specified time points = No) at observation when HRCT of thorax was within normal limits at baseline.
| participants | Inhaled Insulin (Exubera®) | Subcutaneous Insulin |
|---|---|---|
| M12 = Yes | 67 | 64 |
| M12 = No | 4 | 12 |
| M24 = Yes | 38 | 51 |
| M24 = No | 8 | 10 |
| Ext M6 = Yes | 32 | 37 |
| Ext M6 = No | 8 | 8 |
| Ext M18 = Yes | 28 | 33 |
| Ext M18 = No | 8 | 6 |
| Ext M36 = Yes | 22 | 27 |
| Ext M36 = No | 6 | 4 |
Number of subjects with Yes or No responses (within normal limits at specified time points = Yes or not within normal limits at specified time points = No) at observation when HRCT of thorax was not within normal limits at baseline. "No" response at observation further categorized as no significant change (NSC), more abnormal (\> Abn), or less abnormal (\< Abn).
| participants | Inhaled Insulin (Exubera®) | Subcutaneous Insulin |
|---|---|---|
| M12 = Yes | 6 | 5 |
| M12 = No | 20 | 16 |
| M12 = No (NSC) | 19 | 11 |
| M12 = No (> Abn) | 0 | 2 |
| M12 = No (< Abn) | 1 | 3 |
| M24 = Yes | 4 | 6 |
| M24 = No | 17 | 9 |
| M24 = No (NSC) | 17 | 8 |
| M24 = No (> Abn) | 0 | 1 |
| M24 = No (< Abn) | 0 | 0 |
| Ext M6 = Yes | 3 | 3 |
| Ext M6 = No | 16 | 9 |
| Ext M6 = No (NSC) | 15 | 8 |
| Ext M6 = No (> Abn) | 1 | 1 |
| Ext M6 = No (< Abn) | 0 | 0 |
| Ext M18 = Yes | 3 | 2 |
| Ext M18 = No | 14 | 7 |
| Ext M18 = No (NSC) | 12 | 7 |
| Ext M18 = No (> Abn) | 1 | 0 |
| Ext M18 = No (< Abn) | 1 | 0 |
| Ext M24 = Yes | 5 | 2 |
| Ext M24 = No | 9 | 8 |
| Ext M24 = No (NSC) | 8 | 8 |
| Ext M24 = No (> Abn) | 1 | 0 |
| Ext M24 = No (< Abn) | 0 | 0 |
Observed values for insulin antibodies measured as micro units per milliliter (microU/mL).
| microU/mL | Inhaled Insulin (Exubera®) | Subcutaneous Insulin |
|---|---|---|
| Baseline (n=312, 300) | 1.05 (1.05 to 328.00) | 1.05 (1.05 to 1077.00) |
| W3 (n=270, 264) | 1.05 (1.05 to 948.00) | 1.05 (1.05 to 552.00) |
| W6 (n=289, 282) | 4.40 (1.05 to 7296.00) | 1.05 (1.05 to 2123.00) |
| M3 (n=293, 289) | 12.00 (1.05 to 2748.00) | 1.05 (1.05 to 4016.00) |
| W18 (n=275, 280) | 18.00 (1.05 to 1051.00) | 1.05 (1.05 to 3648.00) |
| M6 (n=276, 279) | 20.00 (1.05 to 1424.00) | 1.05 (1.05 to 3380.00) |
| M9 (n=267, 277) | 22.00 (1.05 to 1776.00) | 1.05 (1.05 to 3412.00) |
| M12 (n=263, 263) | 19.00 (1.05 to 1464.00) | 1.05 (1.05 to 1200.00) |
| M15 (n=252, 253) | 20.00 (1.05 to 1760.00) | 1.05 (1.05 to 1780.00) |
| M18 (n=241, 239) | 20.00 (1.05 to 1680.00) | 1.05 (1.05 to 1820.00) |
| M21 (n=234, 233) | 19.00 (1.05 to 1331.00) | 1.05 (1.05 to 2230.00) |
| M24 (n=226, 233) | 20.00 (1.05 to 1330.00) | 1.05 (1.05 to 1965.00) |
| FU M1 (n=247, 226) | 14.00 (1.05 to 974.00) | 1.05 (1.05 to 2135.00) |
| FU M3 (n=249, 229) | 8.50 (1.05 to 686.00) | 1.05 (1.05 to 1070.00) |
| FU M6 (n=250, 227) | 6.55 (1.05 to 641.00) | 1.05 (1.05 to 1480.00) |
| Ext M1 (n=165, 160) | 13.00 (1.05 to 894.00) | 1.05 (1.05 to 1270.00) |
| Ext M3 (n=159, 158) | 15.00 (1.05 to 755.00) | 1.05 (1.05 to 765.00) |
| Ext M6 (n=157, 156) | 12.00 (1.05 to 1200.00) | 1.05 (1.05 to 612.00) |
| Ext M9 (n=150, 157) | 11.50 (1.05 to 1855.00) | 1.05 (1.05 to 905.00) |
| Ext M12 (n=148, 154) | 13.00 (1.05 to 1535.00) | 1.05 (1.05 to 683.00) |
| Ext M15 (n=144, 147) | 10.50 (1.05 to 1860.00) | 1.05 (1.05 to 770.00) |
| Ext M18 (n=140, 144) | 13.00 (1.05 to 1080.00) | 1.05 (1.05 to 455.00) |
| Ext M21 (n=136, 145) | 12.00 (1.05 to 801.00) | 1.05 (1.05 to 620.00) |
| Ext M24 (n=130, 135) | 10.50 (1.05 to 831.00) | 1.05 (1.05 to 696.00) |
| Ext M27 (n=129, 131) | 12.00 (1.05 to 885.00) | 2.50 (1.05 to 208.00) |
| Ext M30 (n=125, 127) | 8.40 (1.05 to 510.00) | 1.05 (1.05 to 429.00) |
| Ext M33 (n=103, 114) | 9.20 (1.05 to 700.00) | 1.05 (1.05 to 637.00) |
| Ext M36 (n=56, 63) | 5.75 (1.05 to 168.00) | 1.05 (1.05 to 321.00) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Inhaled Insulin (Exubera®) | — | 76/316 (24.1%) | 308/316 (97.5%) |
| Subcutaneous Insulin | — | 76/311 (24.4%) | 301/311 (96.8%) |
| Event | Inhaled Insulin (Exubera®) | Subcutaneous Insulin |
|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 4/316 | 12/311 |
| CellulitisInfections and infestations | 7/316 | 5/311 |
| Myocardial infarctionCardiac disorders | 4/316 | 5/311 |
| Chest painGeneral disorders | 2/316 | 5/311 |
| Coronary artery diseaseCardiac disorders | 5/316 | 3/311 |
| Abdominal painGastrointestinal disorders | 0/316 | 4/311 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 4/316 | 1/311 |
| Angina unstableCardiac disorders | 1/316 | 3/311 |
| PneumoniaInfections and infestations | 2/316 | 3/311 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/316 | 3/311 |
| Event | Inhaled Insulin (Exubera®) | Subcutaneous Insulin |
|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 245/316 | 247/311 |
| CoughRespiratory, thoracic and mediastinal disorders | 142/316 | 70/311 |
| Upper respiratory tract infectionInfections and infestations | 104/316 | 101/311 |
| NasopharyngitisInfections and infestations | 83/316 | 94/311 |
| InfluenzaInfections and infestations | 63/316 | 76/311 |
| HypertensionVascular disorders | 52/316 | 62/311 |
| Back painMusculoskeletal and connective tissue disorders | 43/316 | 52/311 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 51/316 | 43/311 |
| TremorNervous system disorders | 37/316 | 50/311 |
| DiarrhoeaGastrointestinal disorders | 49/316 | 27/311 |
| Age, Customized(participants) | Inhaled Insulin (Exubera®) | Subcutaneous Insulin | Total |
|---|---|---|---|
| Between 26 and 35 years | 2 | 7 | 9 |
| Between 36 and 45 years | 36 | 49 | 85 |
| Between 46 and 55 years | 100 | 93 | 193 |
| Between 56 and 65 years | 117 | 101 | 218 |
| Between 66 and 75 years | 61 | 61 | 122 |
| Age Continuous(years) | Inhaled Insulin (Exubera®) | Subcutaneous Insulin | Total |
|---|---|---|---|
| Mean | 56.7 ± 9.2 | 55.5 ± 9.9 | 56.1 ± 9.6 |
| Sex: Female, Male(Participants) | Inhaled Insulin (Exubera®) | Subcutaneous Insulin | Total |
|---|---|---|---|
| Female | 111 | 118 | 229 |
| Male | 205 | 193 | 398 |
The record gives a start of Jun 2002, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2010, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin